Last reviewed · How we verify
Ochsner Health System — Portfolio Competitive Intelligence Brief
4 marketed
0 filed
0 Phase 3
2 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| intravenous NAC | intravenous NAC | marketed | ||||
| Ambrisentan Pill | Ambrisentan Pill | marketed | ||||
| Slow Infusion of Rubidium-82 | Slow Infusion of Rubidium-82 | marketed | Positron emission tomography (PET) imaging agent | Na+/K+-ATPase pump (potassium analog) | Cardiovascular | |
| Furosemide plus Chlorothiazide | Furosemide plus Chlorothiazide | marketed | Loop diuretic + thiazide diuretic combination | Na-K-2Cl cotransporter (NKCC2) and Na-Cl cotransporter (NCC) | Cardiovascular |
Therapeutic area mix
- Cardiovascular · 2
- Immunology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Centre hospitalier de l'Université de Montréal (CHUM) · 1 shared drug class
- Eastern Health, Canada · 1 shared drug class
- National Heart, Lung, and Blood Institute (NHLBI) · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Ochsner Health System:
- Ochsner Health System pipeline updates — RSS
- Ochsner Health System pipeline updates — Atom
- Ochsner Health System pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Ochsner Health System — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ochsner-health-system. Accessed 2026-05-16.